[New drugs in oncology]
1Medizinische Klinik 1 (Gastroenterologie, Hepatologie, Infektiologie), Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland, nisar.malek@med.uni-tuebingen.de.
Background:
Drug development in oncology has seen major innovations in recent years. Based on the molecular changes found in malignant tumors, new drugs are being developed which specifically target these altered signaling pathways.
Results:
In addition to the already broadly used inhibitors of growth factor and angiogenic signaling pathways, new and innovative target structures have been identified. Cancer stem cells which are thought to be the reason for drug resistance and tumor recurrence are now being targeted. c-MET signaling has emerged as an important new signaling module which can be influenced pharmacologically. Inhibitors of immune checkpoints like antibodies which target the CTLA4 molecule are leading to impressive results in clinical trials. Drugs which influence the epigenetic changes found in tumor cells are tested specifically for their ability to overcome drug resistance. Finally, treatment with oncolytic viruses has made a comeback in certain tumor entities.
Conclusion:
Oncological treatments will see a significant addition of new drugs and treatment options in the next few years which will hopefully improve the survival of patients with tumors.
Insights
Recent oncology drug development targets molecular changes in tumors, including cancer stem cells and c-MET signaling. Innovative treatments like immune checkpoint inhibitors and oncolytic viruses show promise for improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Recent innovations in oncology drug development focus on targeting specific molecular alterations in malignant tumors.
- Personalized medicine approaches are increasingly utilized, tailoring treatments to individual tumor characteristics.
Purpose of the Study:
- To review emerging therapeutic targets and novel drug candidates in oncology.
- To highlight advancements in overcoming drug resistance and improving patient outcomes.
Main Methods:
- Review of current research and clinical trial data on novel oncological treatments.
- Analysis of targeted therapies, including small molecule inhibitors and immunotherapies.
- Evaluation of emerging treatment modalities such as oncolytic viruses and epigenetic drugs.
Main Results:
- New targets identified, including cancer stem cells and c-MET signaling pathways.
- Immune checkpoint inhibitors (e.g., CTLA4 antibodies) demonstrate significant clinical trial success.
- Epigenetic drugs and oncolytic viruses show potential in overcoming drug resistance and treating specific tumor types.
Conclusions:
- The next few years will bring significant advancements in oncological treatments.
- New drugs and therapeutic options are expected to improve patient survival rates in cancer care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers